Clik here to view.
FDA proposes accelerated approval of early-stage Alzheimer’s drugs based on...
TweetPittsburgh compound B staining in AD. Source: National Institute on Aging/NIH. In our February 28, 2013 article on the Biopharmconsortium Blog, we discussed the FDA’s February 7, 2013 Draft...
View ArticleClik here to view.
Does inflammation in the brain cause aging?
TweetHypothalamic nuclei on one side of the hypothalamus, in 3-D. Source: Was a bee. http://bit.ly/13o91HU The Biopharmconsortium Blog has been following novel developments in anti-aging medicine and...
View ArticleClik here to view.
Will Novartis lead a pharma industry return to neuroscience R&D?
TweetPyramidal neurons. Source: Retama. http://bit.ly/18j9iOP A prominent feature of pharmaceutical company strategy in recent years has been massive cuts in R&D. These cutbacks have hit...
View ArticleClik here to view.
Neuroscience companies sprout up in Boston
TweetPyramidal neurons. Source: Magnus Manske http://bit.ly/1gUo6GM In our December 10, 2013 blog article that focused on Novartis’ new neuroscience division, we briefly mentioned two young Cambridge...
View ArticleClik here to view.
The Genentech/NewLink alliance, the IDO/TDO pathway, and targeting metabolism...
TweetIndoleamine 2,3-dioxygenase 1 On October 20, 2014, New Link Genetics Corporation (Ames, IA) announced that it had entered into an exclusive worldwide license agreement with Genentech/Roche for...
View ArticleClik here to view.
New genetics study supports the amyloid hypothesis of Alzheimer’s disease–but...
Tweet The APP processing pathway An exciting new study on Alzheimer’s disease (AD) was published in the 2 August issue of Nature. The study was carried out by researchers at deCode Genetics...
View ArticleClik here to view.
Here we go again–Lilly’s Alzheimer’s drug solanezumab fails to show efficacy...
Tweet Amyloid precursor protein (APP) As we mentioned in our August 19, 2012 article on Alzheimer’s disease (AD), the results of Phase 3 trials of Lilly’s amyloid-targeting monoclonal antibody (MAb)...
View ArticleClik here to view.
Alzheimer’s disease–where do we go from here?
Tweet New Alzheimer’s disease model, the CVN mouse Our August 19, 2012 and our August 28, 2012 articles on this blog focused on the latest developments in Alzheimer’s disease (AD) drug development....
View ArticleClik here to view.
Identification of a novel Alzheimer’s disease pathway provides potential new...
Tweet Neurofibrillary tangle. In August and September of 2012, we published three articles on Alzheimer’s disease on the Biopharmconsortium Blog: New genetics study supports the amyloid hypothesis of...
View ArticleClik here to view.
FDA publishes Draft Guidance on developing drugs for early stages of...
Tweet Normal and Alzheimer’s brains compared. Once again, approaches to improving clinical trials for candidate disease-modifying drugs for Alzheimer’s disease (AD) are in the news. On February 7,...
View ArticleClik here to view.
“Our Promise to Nicholas”, Batten disease, and gene therapy
Tweet Wayland MA Source: http://bit.ly/1N1TyRk Russell’s Garden Center, on Route 20, a family-owned business established in 1876, is a unique Wayland MA institution. When you shop at Russell’s and...
View ArticleClik here to view.
New genetics study supports the amyloid hypothesis of Alzheimer’s disease–but...
The APP processing pathway An exciting new study on Alzheimer’s disease (AD) was published in the 2 August issue of Nature. The study was carried out by researchers at deCode Genetics (Reykjavik...
View ArticleClik here to view.
Here we go again–Lilly’s Alzheimer’s drug solanezumab fails to show efficacy...
Amyloid precursor protein (APP) As we mentioned in our August 19, 2012 article on Alzheimer’s disease (AD), the results of Phase 3 trials of Lilly’s amyloid-targeting monoclonal antibody (MAb) drug...
View ArticleClik here to view.
Alzheimer’s disease–where do we go from here?
New Alzheimer’s disease model, the CVN mouse Our August 19, 2012 and our August 28, 2012 articles on this blog focused on the latest developments in Alzheimer’s disease (AD) drug development. To...
View ArticleClik here to view.
Identification of a novel Alzheimer’s disease pathway provides potential new...
Neurofibrillary tangle. In August and September of 2012, we published three articles on Alzheimer’s disease on the Biopharmconsortium Blog: New genetics study supports the amyloid hypothesis of...
View ArticleClik here to view.
FDA publishes Draft Guidance on developing drugs for early stages of...
Normal and Alzheimer’s brains compared. Once again, approaches to improving clinical trials for candidate disease-modifying drugs for Alzheimer’s disease (AD) are in the news. On February 7, 2013,...
View ArticleClik here to view.
FDA proposes accelerated approval of early-stage Alzheimer’s drugs based on...
Pittsburgh compound B staining in AD. Source: National Institute on Aging/NIH. In our February 28, 2013 article on the Biopharmconsortium Blog, we discussed the FDA’s February 7, 2013 Draft Guidance...
View ArticleClik here to view.
Does inflammation in the brain cause aging?
Hypothalamic nuclei on one side of the hypothalamus, in 3-D. Source: Was a bee. http://bit.ly/13o91HU The Biopharmconsortium Blog has been following novel developments in anti-aging medicine and...
View ArticleClik here to view.
Will Novartis lead a pharma industry return to neuroscience R&D?
Pyramidal neurons. Source: Retama. http://bit.ly/18j9iOP A prominent feature of pharmaceutical company strategy in recent years has been massive cuts in R&D. These cutbacks have hit especially hard...
View ArticleClik here to view.
Neuroscience companies sprout up in Boston
Pyramidal neurons. Source: Magnus Manske http://bit.ly/1gUo6GM In our December 10, 2013 blog article that focused on Novartis’ new neuroscience division, we briefly mentioned two young Cambridge MA...
View Article
